Prestige Consumer Healthcare (PBH) Cash & Equivalents (2010 - 2026)

Prestige Consumer Healthcare has reported Cash & Equivalents for 17 years, with the latest figure at $63.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 34.75% year-over-year to $63.9 million in Q1 2026; TTM through Mar 2026 was $63.9 million, a 34.75% decrease from a year earlier, with the FY2026 full-year figure at $63.9 million, down 34.75% from the prior year.
• Cash & Equivalents was $63.9 million for Q1 2026 at Prestige Consumer Healthcare, up from $62.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $139.5 million in Q2 2025, with the low at $27.2 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $64.4 million, with a median of $58.5 million recorded in 2023.
• The largest YoY upside for Cash & Equivalents was 310.88% in 2022 against a maximum downside of 78.08% in 2022.
• Over 5 years, Cash & Equivalents stood at $86.4 million in 2022, then fell by 26.34% to $63.6 million in 2023, then retreated by 20.03% to $50.9 million in 2024, then climbed by 22.6% to $62.4 million in 2025, then rose by 2.4% to $63.9 million in 2026.
• The last three Cash & Equivalents figures came in at $63.9 million (Q1 2026), $62.4 million (Q4 2025), and $119.1 million (Q3 2025), per Business Quant data.